Levaquin - medication PDF

Preview

Summary

medication...

Description

BHS School of Health Professions DPN Medication Tracking Sheet (Handwritten in Ink)

Student Name: ___Reynaldo Mireles____

Reference: □ Davis □ Lexicomp □ Other: _____ATI_____________________________________ Generic drug name: _Levofloxacin_______ Trade Name: __Levaquin________________________ Therapeutic Drug Classification: ____Antiinfective_________________________________________ Pharmacologic Drug Classification: ___Antibiotic_________________________________________ Pregnancy Category: ____C______ Breastfeeding Considerations: _______________________________ Routes of Administration: □ PO □ NG □ Peg □ Subcutaneous □ Intramuscular □ Topical □ Rectal □ Nasal □ Eye □ Ear □ IV Uses: ____Effective against gram-positive and gram-negative organisms____________________________________________ Drug Action: ______antibiotic that inhibits DNA-gyrase, an enzyme necessary for bacterial replication, transcription, repair, and recombination.____________ Normal Dosage Range based on route: _____PO 500 mg q24h x 10 d ___________________ __________________________________________________________________________________________ Maximum Dosage in 24 hours: ___500mg______________________________________________ Adverse Reactions/Side Effects related to: Respiratory/Oxygenation: _____________________________________________________________ Cardiac, Blood Pressure, Pulse: ________________________________________________________ Level of Consciousness: ___headache, insomnia, dizziness, decreased vision_________________________________ Other common effects: __Nausea, diarrhea, constipation, vomiting, abdominal pain, dyspepsia. __________________________ Other life-threatening reactions (*CAPITALS): __________________________________________ ___________________________________________________________________________________ Nursing Implications related to: □ Give with Full glass of water □ Give with food □ Give on Empty Stomach □ Do Not Crush Applicable Lab values: _C&S prior beginning therapy_________________________ ___________________________________________________________________________________

Assessment: __assess for adverse effects, any sign of hallucinations, depression, skin eruption, skin rash, seizures, restlessness, confusion. ___________________ ___________________________________________________________________________________ Other Implications: _________________________________________________________________ Patient Teaching: __avoid exposure to excess sunlight, avoid NSAIDS while taking medication, consume fluids liberally, learn important indications for discontinuing drug and notify physician immediately. ________ __________________________________________________________________________________________

(Complex and later courses, complete IV section) Administer: □ Diluted □ Undiluted

IV Administration: □ IV Push □ IV Piggy Back

□ IV Pump: □ Continuous infusion □ Intermittent infusion

Normal Dose base on route/therapeutic effect: _IV 500 mg infused over 60 min q24h x 7–14 d ____ Maximum dosage: _____500 mg_______________________________________________________ Dilute with _________D5W, NS, D5/NS, D5/RL______

Pedi Administration Consideration (if applicable): _______________________________________________ ___________________________________________________________________________________________ IV Medication Incompatibilities: _____Amiodarone, azithromycin ___________________________________________________________________________________________ ___________________________________________ ___________________________________________________________________________________________ Other considerations: _______________________________________________________________________ ___________________________________________________________________________________________ ___________________________________________________________________________________________ Student: Document in the Table below every time this medication is administered during your nursing program: Date :

Reason for Use With this Patient :

Ordered Dose Route & Frequenc y

For IV: Primary Solutio n& Rate

Comments re: Dosage or Administration :

Evaluatio n of Pt Response:

Revised 07/2018 ML...